In Re Regulus Therapeutics Inc. Securities Litigation
Opinion
Trial Court Opinion
UNITED STATES DISTRICT COURT SOUTHERN DISTRICT OF CALIFORNIA 11 IN RE REGULUS Case No.: 3:17-cv-0182-BTM-RBB
THERAPEUTICS INC.
SECURITIES LITIGATION ORDER GRANTING
DEFENDANTS’ MOTION TO
DISMISS AND GRANTING
PLAINTIFFS LEAVE TO AMEND
16 [ECF No. 22] 17 18
20 This is a putative securities class action filed on behalf of all purchasers of 21 common shares of Regulus Therapeutics, Inc. (“Regulus”) between February 17, 22 2016 and June 12, 2017, inclusive (the “Class Period”). Plaintiffs allege that 23 Defendants Regulus, Joseph P. Hagan, Paul C. Grint, M.D., and Michael Huang, M.D. made misleading statements regarding a pharmaceutical product being
26 1 Defendant Grint was Regulus’s Chief Executive Officer (“CEO”) from June 1, 2015 through his resignation on May 4, 2017. (ECF No. 19, ¶ 17.) Defendant 28 developed by Regulus that artificially inflated its common stock prices during the Class Period. Based thereon, Plaintiffs assert claims for violation of Section 10(b) of the Securities Exchange Act, 15…